TY - JOUR T1 - Interferon gamma release assays based on M. tuberculosis-specific antigens (IGRAs) in sarcoidosis patients JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA3315 VL - 46 IS - suppl 59 SP - PA3315 AU - Anna Kempisty AU - Beata Bialas-Chromiec AU - Dagmara Borkowska AU - Jan Kus Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA3315.abstract N2 - Introduction: Diagnosis of sarcoidosis relies on properly conducted differential diagnosis of disorders with similar clinical and histopathological features. Exclusion of active tuberculosis during differential diagnosis is not equal to exclusion of latent tuberculosis infection (LTBI). In sarcoidosis patients, this aspect is particularly important in those who are going to be treated with immunosuppressive drugs. In patients with sarcoidosis, the use of IGRAs in detection of LTBI may have a limited specifity, as has been shown in the studies based on molecular and immunological methods, which concerned participation of tubercle bacillus antigens in the ethiopathogenensis of sarcoidosis.Object and rationale: The aim of the study was to assess the results of two commercial IGRAs in the group of untreated sarcoidosis patients formerly BCG vaccinated.Material and methods: 151 patients, mean age 38 ± 10.3,with newly diagnosed pulmonary sarcoidosis were enrolled into the study. All participants underwent QFT-GIT assay. A subgroup of 81 patients underwent also T-SPOT.TB assay.Results: QFT-GIT was positive in 7/151. T-SPOT.TB was positive in 3/81. There were no indeterminate results in both IGRAs. There was no statistically significant relationship between IGRAs results and sarcoidosis parameters such as the radiologic stage, disease duration and the presence of Löfgren's syndrome.Conclusions: In sarcoidosis patients formerly BCG vaccinated, positive rate of IGRAs was 4.6% for QFT-GIT and 3.7% for T-SPOT.TB. We did not find the influence of the selected parameters of sarcoidosis on IGRAs results. ER -